Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type I matrix metalloproteinase (MTI-MMP) correlate with melanoma progression

Journal of Pathology

Volumn 191, Issue 3, 2000, Pages 245-256

  Hofmann, Uta B ^a,b,c   Westphal, Johan R ^a   Zendman, Albert J W ^a   Becker, Jürgen C ^b   Ruiter, Dirk J ^a   Van Muijen, Goos N P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Invasion; Melanoma; MMP 2; MT1 MMP; TIMP 2; Xenograft

Indexed keywords

COLLAGENASE; GELATINASE A; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; ENZYME ACTIVATION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT; ZYMOGRAPHY;

EID: 0033923006     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9896(2000)9999:9999<::aid-path632>3.0.co;2-%23     Document Type: Article

References (43)

1. Stetler Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumour invasion and metastasis. FASEB J 1993; 7: 1434-1441.
2. Stetler Stevenson WG, Aznavoorian S, Liotta LA. Tumour cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-573.
3. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3: 895-904.
4. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270.
5. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-308.
6. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J 1999; 13: 781-792.
7. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
8. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells [see comments]. Nature 1994; 370: 61-65.
9. Tanaka M, Sato H, Takino T, Iwata K, Inoue M, Seiki M. Isolation of a mouse MT2-MMP gene from a lung cDNA library and identification of its product. FEBS Lett 1997; 402: 219-222.
10. Puente XS, Pendas AM, Llano E, Velasco G, Lopez Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56: 944-949.
11. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231: 602-608.
12. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem 1999; 274: 8925-8932.
13. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-160.
14. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure., regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
15. Butler GS, Butler MJ, Atkinson SJ, et al The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998; 273: 871-880.
16. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-693.
17. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.
18. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271: 9135-9140.
19. Nagase H. Cell surface activation of progelatinase A (pro-MMP-2) and cell migration. Cell Res 1998; 8: 179-186.
20. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 1996; 271: 17119-17123.
21. Nakahara H, Howard L, Thompson EW. et al. Transmembrane/ cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci U S A 1997; 94: 7959-7964.
22. Kurschat P, Zigrino P, Nischt R, et al. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinasc-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 1999; 274: 21056-21062.
23. Zucker S, Drews M. Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MTI-MMP). J Biol Chem 1998; 273: 1216-1222.
24. Strongin AY, Marmer BL, Grant GA, Goldberg GI. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem 1993; 268: 14033-14039.
25. de Vries TJ, Quax PH, Denijn M, et al. Plasminogen activators., their inhibitors., and urokinasc receptor emerge in late stages of melanocytic tumour progression. Am J Pathol 1994; 144: 70-81.
26. Vaisanen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactivc protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 51-58.
27. van den Oord JJ, Paemcn L, Opdenakker G, de Wolf Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665-670.
28. Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283-289.
29. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MTMMP) and with lymph node metastasis. Int J Cancer 1995; 64: 355-359.
30. Nomura H, Sato H, Seiki M, Mai M, Okada Y, Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-3266.
31. Yamamoto M, Mohanam S, Sawaya R, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumours in vivo and in vitro. Cancer Res 1996; 56: 384-392.
32. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999; 59: 467-473.
33. Nakada M, Nakamura H, Ikeda E. et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumours. Am J Pathol 1999; 154: 417-428.
34. van Muijen GN, Cornelissen LM, Jansen CF, et al. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 1991; 9: 259-272.
35. van Muijen GN, Jansen KF, Cornelissen IM, Smeets DF, Beck JL, Ruiter DJ. Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int J Cancer 1991; 48: 85-91.
36. Westphal JR, van't Hullenaar RG, van der Laak JA, et al. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 1997; 76: 561-570.
37. Grant GM, Cobb JK, Castillo B, Klebe RJ. Regulation of matrix metalloproteinases following cellular transformation. J Cell Physiol 1996; 167: 177-183.
38. Morgunova E, Tuuttila A, Bergmann U, et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed [see comments]. Science 1999; 284: 1667-1670.
39. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumour cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998; 58: 3743-3750.
40. de Vries TJ, van Muijen GN, Ruiter DJ. The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res 1996; 6: 79-88.
41. Ferrier CM, Van-Muijen GN, Ruiter DJ. Proteases in cutaneous melanoma. Am Med 1998; 30: 431-442.
42. Stanton H, Gavrilovic J, Atkinson SJ, et al. The activation of pro-MMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 1998; 111: 2789-2798.
43. Lambert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumours. Am J Pathol 1998; 153: 429-437.